These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

369 related items for PubMed ID: 17286767

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Recombinant factor concentrates may increase inhibitor development: a single centre cohort study.
    Strauss T, Lubetsky A, Ravid B, Bashari D, Luboshitz J, Lalezari S, Misgav M, Martinowitz U, Kenet G.
    Haemophilia; 2011 Jul; 17(4):625-9. PubMed ID: 21299743
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Influence of the type of F8 gene mutation on inhibitor development in a single centre cohort of severe haemophilia A patients.
    Gouw SC, Van Der Bom JG, Van Den Berg HM, Zewald RA, Ploos Van Amstel JK, Mauser-Bunschoten EP.
    Haemophilia; 2011 Mar; 17(2):275-81. PubMed ID: 21070499
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Risk of inhibitor development in mild haemophilia A increases with age.
    Mauser-Bunschoten EP, Den Uijl IE, Schutgens RE, Roosendaal G, Fischer K.
    Haemophilia; 2012 Mar; 18(2):263-7. PubMed ID: 21851507
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Factor VIII inhibitors in patients with hemophilia A: epidemiology of inhibitor development and induction of immune tolerance for factor VIII.
    Kreuz W, Becker S, Lenz E, Martinez-Saguer I, Escuriola-Ettingshausen C, Funk M, Ehrenforth S, Auerswald G, Kornhuber B.
    Semin Thromb Hemost; 1995 Mar; 21(4):382-9. PubMed ID: 8747701
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Epidemiology of inhibitors and current treatment strategies.
    Kreuz W, Ettingshausen CE, Auerswald G, Saguer IM, Becker S, Funk M, Heller C, Klarmann D, Klingebiel T, GTH PUP Study Group.
    Haematologica; 2003 Jun; 88(6):EREP04. PubMed ID: 12826530
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Experience with a third generation recombinant factor VIII concentrate (Advate) for immune tolerance induction in patients with haemophilia A.
    Valentino LA, Recht M, Dipaola J, Shapiro AD, Pipe SW, Ewing N, Urgo J, Bullock T, Simmons M, Deguzman C.
    Haemophilia; 2009 May; 15(3):718-26. PubMed ID: 19298383
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Inhibitors: our greatest challenge. Can we minimize the incidence?
    Kruse-Jarres R.
    Haemophilia; 2013 Jan; 19 Suppl 1():2-7. PubMed ID: 23278993
    [Abstract] [Full Text] [Related]

  • 19. Immune tolerance induction with a high purity von Willebrand factor/VIII complex concentrate in haemophilia A patients with inhibitors at high risk of a poor response.
    Gringeri A, Musso R, Mazzucconi MG, Piseddu G, Schiavoni M, Pignoloni P, Mannucci PM, RITS-FITNHES Study Group.
    Haemophilia; 2007 Jul; 13(4):373-9. PubMed ID: 17610550
    [Abstract] [Full Text] [Related]

  • 20. Inhibitor development in hemophiliacs: the roles of genetic versus environmental factors.
    Lee CA, Lillicrap D, Astermark J.
    Semin Thromb Hemost; 2006 Jun; 32 Suppl 2():10-4. PubMed ID: 16804830
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 19.